| Ytd | ||
| 1y |
| Open | 5.41 | Prev Close | 5.38 | Low | 5.34 | High | 5.43 | Mkt Cap | 242.79M |
| Vol | 0.00 | Avg Vol | 262.78K | EPS | -1.24 | P/E | -4.34 | Forward P/E | -7.01 |
| Beta | 2.12 | Short Ratio | 10.80 | Inst. Own | 92.38% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | N/A | 50-d Avg | 5.38 | 200-d Avg | 7.01 | 1yr Est | 19.00 |
THRD News
Stockholders overwhelmingly approved liquidation and dissolution of the Company at the June 5, 2025
Board of Directors has approved plan to liquidate and intends to seek stockholder approval for disso
Recently presented THB335 Phase 1 data support advancement into Phase 2 clinical trial in chronic sp
The heavy selling pressure might have exhausted for Third Harmonic Bio, Inc. (THRD) as it is technic
Third Harmonic Bio, Inc. (THRD) might move higher on growing optimism about its earnings prospects,
The heavy selling pressure might have exhausted for Third Harmonic Bio, Inc. (THRD) as it is technic
On Tuesday, Third Harmonic Bio, Inc. THRD revealed results from its Phase 1 single and multiple asce
THB335 Phase 1 data support advancement into Phase 2 clinical trial in chronic spontaneous urticari
SAN FRANCISCO, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a clinical
The average of price targets set by Wall Street analysts indicates a potential upside of 26.7% in Th
SAN FRANCISCO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a clinical
THB335 Phase 1 SAD/MAD clinical trial on track to deliver clinical results in 1Q'25 Strong financial
SAN FRANCISCO, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a clinica
SAN FRANCISCO, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a clinical
THB335 Phase 1 SAD/MAD clinical trial progressing; study now on track to report clinical results in
SAN FRANCISCO, May 28, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a clinical-
U.S. FDA clears Investigational New Drug application for THB335 Phase 1 SAD/MAD clinical trial initi
SAN FRANCISCO, March 28, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a biophar
U.S. IND filed for THB335 with anticipated clinical trial start during 2Q'24 Strong financial positi
SAN FRANCISCO, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a biopharm
On Thursday, 241 companies hit new 52-week lows.